Background Cannabis may be used for cancer pain relief, also in concomitance with anticancer chemotherapy. However, herb-drug interactions can lead to potentially severe and even life-threatening adverse reactions. For instance, inhibition or induction of CYP enzymes by herbal compounds can alter the ADME process of co-administered drugs. This study aims to investigate the potential effects of phytocannabinoids from Cannabis extracts (CE), on drug transporters, cannabinoid receptors and proteins involved in nociception in human colon cancer cell lines. Methods Ethanolic extracts of Cannabis flos were titrated in HPLC-MS e HPLC-MS/MS. Human colon carcinoma cells sensitive (LoVo) and resistant to doxorubicin (DOX) (LoVo/DOX) were used. Total RNA of study genes was isolated and reverse transcribed. MDR1, CNR1, CNR2 and TRPV1 gene expression levels were evaluated using the housekeeping gene, 18 s rRNA, as endogenous control to normalize data. Results THC was 0.14% in Cannabis ethanolic extract. In CE untreated cells, basal gene expression levels of CNR1, CNR2 and MDR1 were higher in Lovo/DX cells as compared to LoVo cells. No substantial differences between the two cell lines for TRPV1 expression was observed. Conclusions In vitro studies on the effects of CE and their combinations with selected anticancer drugs in human colon cancer cells are ongoing. The results of our studies upon completion will contribute to understanding in vitro interactions between cannabis extracts and anticancer agents.
P118 A preliminary study for evaluation of cannabis - chemotherapy interactions on human colon cancer cells / Maggini V, Gallo E, Landini I, Lapucci A, Nobili S, Mini E, Firenzuoli F. - In: BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE. - ISSN 1472-6882. - ELETTRONICO. - 17:(2017), pp. 115-115. [10.1186/s12906-017-1783-3]
P118 A preliminary study for evaluation of cannabis - chemotherapy interactions on human colon cancer cells
Maggini V;Landini I;Lapucci A;Nobili S;Mini E;Firenzuoli F
2017
Abstract
Background Cannabis may be used for cancer pain relief, also in concomitance with anticancer chemotherapy. However, herb-drug interactions can lead to potentially severe and even life-threatening adverse reactions. For instance, inhibition or induction of CYP enzymes by herbal compounds can alter the ADME process of co-administered drugs. This study aims to investigate the potential effects of phytocannabinoids from Cannabis extracts (CE), on drug transporters, cannabinoid receptors and proteins involved in nociception in human colon cancer cell lines. Methods Ethanolic extracts of Cannabis flos were titrated in HPLC-MS e HPLC-MS/MS. Human colon carcinoma cells sensitive (LoVo) and resistant to doxorubicin (DOX) (LoVo/DOX) were used. Total RNA of study genes was isolated and reverse transcribed. MDR1, CNR1, CNR2 and TRPV1 gene expression levels were evaluated using the housekeeping gene, 18 s rRNA, as endogenous control to normalize data. Results THC was 0.14% in Cannabis ethanolic extract. In CE untreated cells, basal gene expression levels of CNR1, CNR2 and MDR1 were higher in Lovo/DX cells as compared to LoVo cells. No substantial differences between the two cell lines for TRPV1 expression was observed. Conclusions In vitro studies on the effects of CE and their combinations with selected anticancer drugs in human colon cancer cells are ongoing. The results of our studies upon completion will contribute to understanding in vitro interactions between cannabis extracts and anticancer agents.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
